BioCorRx to Present at 10th Annual Singular Research Investor Conference on September 17, 2015
GlobeNewswire - Thu Sep 10, 7:00AM CDT
BioCorRx, Inc. (OTCQX: BICX), developer of the Start Fresh Program, a Medication-Assisted Treatment (MAT) program, today announced that Brady Granier, Interim Chief Executive Officer, will present at the 10 Annual Singular Research Best of the Uncovereds Investor Conference being held on September 17, 2015 in Los Angeles.
BioCorRx, Inc. Announces Agreement with Four Additional Wellness Centers in California and Illinois
GlobeNewswire - Wed Sep 09, 7:00AM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program, a Medication-Assisted Treatment (MAT) program, announces new distribution agreements to bring the Start Fresh Program into four additional wellness centers. The agreements are part of the company's continued focus to distribute its addiction treatment program to wellness centers nationally through a partnership with Myriad Medical Marketing (MMM). The new centers are Wellness Institute of Illinois, Coastside Health and Medical Clinic, INC., Mazolewski OC Medical PC, and COR Medical Group.
BioCorRx, Inc. Announces Start Fresh Program(r) Agreement with Two Additional Wellness Centers
GlobeNewswire - Thu Sep 03, 7:00AM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program, a Medication-Assisted Treatment (MAT) program, announces distribution agreements to bring the Start Fresh Program into two additional wellness centers. The agreement is part of the company's continued focus to distribute its addiction treatment program to wellness centers nationally through a partnership with Myriad Medical Marketing (MMM). The new centers are Escalon Physical Medicine and Scott Medical Health Center PC. "The upcoming availability of our program at two new centers is exciting as they will be continuing our mission of greater accessibility of the Start Fresh Program throughout the country," stated COO & interim CEO, Brady Granier.
SeeThruEquity Initiates Coverage on BioCorRx Inc. with a Price Target of $0.13
ACCESSWIRE - Wed Jul 22, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / July 22, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of BioCorRx Inc. (OTCQB: BICX) with a Price Target of $0.13.
BioCorRx, Inc. Chief Financial Officer, Lourdes Felix and Brady Granier, Chief Operating Officer and Interim Chief Executive Officer, Discuss Recent News in a New Audio Interview at SmallCapVoice.com
GlobeNewswire - Mon Jul 20, 7:00AM CDT
SmallCapVoice.com, Inc. (SCV) and BioCorRx, Inc. (OTCQB:BICX) developer of the Start Fresh Program (R) used for the treatment of alcohol and opioid dependence, announced today that a new audio interview is now available. The interview can be heard at http://smallcapvoice.com/blog/7-16-15-smallca...x-inc-bicx
BioCorRx, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
GlobeNewswire - Wed Jul 08, 7:00AM CDT
BioCorRx Inc. (OTCQB:BICX), developer of the Start Fresh Program (R) used for the treatment of alcohol and opioid dependence, today announced that it has retained Maxim Group LLC, a leading investment banking, securities, and investment firm, to provide strategic corporate planning and investment banking services. Maxim will focus on assisting BioCorRx in its strategies for maximizing shareholder value through its full scope of investment banking services.
BioCorRx, Inc. Finalizes Asset Purchase Agreement to Acquire Naltrexone Implant Formula for Treating Addiction
GlobeNewswire - Tue Jul 07, 7:00AM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program(R) used for the treatment of alcohol and opioid dependence, announces the finalization of an asset purchase agreement with Trinity Compound Solutions (formerly Trinity Rx Solutions) ("Trinity"
BioCorRx, Inc. Announces First Patients Treated in Wellness Center Pilot Using the Start Fresh Program
GlobeNewswire - Mon Jul 06, 7:00AM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces update on the Company's pilot program with Myriad Medical Marketing (MMM). The first location in the pilot program, Corona Physical Medicine (CPM), has just treated their first three patients using the Start Fresh Program. CPM is located at 1150 El Camino Avenue, Suite 108, Corona, CA 92879.
BioCorRx, Inc. and Sobriety and Addiction Solutions, LLC Announce Mutual Separation; Plan to Advocate for Wider Naltrexone Implant Use in the Treatment of Addiction
GlobeNewswire - Thu Jul 02, 1:55PM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces the mutual release of Sobriety and Addiction Solutions, LLC (SAS) from its license agreements with the Company. They were previously offering the Start Fresh Program for locations in Walnut Creek, Fresno and Washington D.C. under MyLife Recovery Centers (MyLife). With different views on how to best approach and capture market share of the $35 billion addiction treatment industry, the companies felt that this separation would allow each party to pursue their respective strategies to help more people suffering from addiction in the largely fragmented addiction treatment market.
BUYINS.NET Updates BioCorRx (BICX) SqueezeTrigger Report
M2 - Wed Jun 10, 8:56AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on BioCorRx (OTC: BICX) after releasing the latest short sale data through June 9, 2015. The total aggregate number of shares shorted since August 2010 is approximately 55.6 million shares. Approximately 24.95% of daily trading volume is short selling. The SqueezeTrigger price for all BICX shares shorted is $0.22. A short squeeze is expected to begin when shares of BICX close above the $0.22 SqueezeTrigger price.
BioCorRx Inc. Reports First Quarter 2015 Financial Results
GlobeNewswire - Wed May 20, 2:08PM CDT
BioCorRx Inc. Reports First Quarter 2015 Financial Results
BioCorRx, Inc. and Start Fresh Featured on MSNBC, SAMHSA and NIAAA Endorse Medication for Treatment of Alcohol Abuse Disorders
GlobeNewswire - Tue Apr 28, 7:00AM CDT
BioCorRx, Inc. (BICX) announces MSNBC segment featuring Brady Granier, COO and interim CEO, alongside Start Fresh Program and Growing Pains alum, Jeremy Miller. The two were interviewed by Tamron Hall of NewsNation to discuss Jeremy's success with the Start Fresh Program, a medication-assisted treatment program developed by BioCorRx that is used to treat alcohol and opioid addiction. The MSNBC segment originally aired on April 21, 2015 and can be viewed online here.
BioCorRx, Inc. Announces Start Date of Start Fresh Program(r) Pilot at Wellness Center in Corona, CA
GlobeNewswire - Tue Apr 14, 7:00AM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces that the Company's pilot program that was created as a result of an agreement with Myriad Medical Marketing (MMM) is scheduled to launch later this month. As of April 27, 2015 Corona Physical Medicine (CPM) in Corona, CA plans to begin setting appointments with potential patients. CPM is located at 1150 El Camino Avenue, Suite 108, Corona, CA 92879. This will be the first of five planned locations to participate in the Start Fresh pilot program. Upon successful completion of the pilot program, MMM will begin to introduce the Start Fresh Program to other wellness centers nationwide.
BioCorRx, Inc. Reports 2014 Financial Results
GlobeNewswire - Thu Apr 02, 7:00AM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program(R) used for the treatment of alcohol and opioid dependence, announces its 2014 Financial Results with highlights as follows:
Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S.
PR Newswire - Fri Mar 27, 5:23PM CDT
BioCorRx, Inc. (BICX) operating in Santa Ana, California is a healthcare solutions organization, which focuses solely on addiction treatment; the market for which is estimated at $22 billion in the U.S. alone. The Company created a unique treatment program which includes the use of FDA-approved Naltrexone in a specially compounded form for outpatient surgical implantation. The Company has exclusive rights (excluding Australia and New Zealand) to the specially formulated Naltrexone implant. The treatment program also includes an outpatient coaching regimen in which patients receive psycho-social therapy and support for their alcohol or substance abuse addictions.
/DISREGARD RELEASE: Small Cap IR/
PR Newswire - Fri Mar 27, 10:12AM CDT
We are advised by Small Cap IR that journalists and other readers should disregard the news release, BioCorRX Inc. Positions Itself Through New Acquisitions, And Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S.: Analyst Report Issued by Small Cap IR, issued 27-Mar-2015 over PR Newswire. A corrected release will be issed later today.
BioCorRX Inc. Positions Itself Through New Acquisitions, And Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S.: Analyst Report Issued by Small Cap IR
PR Newswire - Fri Mar 27, 6:00AM CDT
BioCorRx, Inc. (OTCBB: BICX) operating in Santa Ana, California is a healthcare solutions organization, which focuses solely on addiction treatment; the market for which is estimated at $22 billion in the U.S. alone. The Company utilizes a unique treatment regiment through the use of FDA-approved Naltrexone, which the Company has exclusive rights to (excluding Australia and New Zealand). This program is also supplemented with heavy life coaching in which patients receive further treatment for their alcohol or substance abuse addictions.
Brady Granier, Chief Operating Officer and Interim Chief Executive Officer of BioCorRx, Inc., Discusses Recent News in a New Audio Interview at SmallCapVoice.com
GlobeNewswire - Thu Mar 26, 7:00AM CDT
SmallCapVoice.com, Inc. (SCV) announced today that a new audio interview with BioCorRx, Inc. (OTC QB:BICX), developer of the Start Fresh Program, is now available. The interview can be heard at http://smallcapvoice.com/blog/3-24-15-smallca...x-inc-bicx.
BioCorRx, Inc. Enters Definitive Agreement with Myriad Medical Marketing to Introduce Start Fresh Program to Wellness Centers
GlobeNewswire - Wed Mar 25, 7:00AM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces the execution of a definitive agreement with Myriad Medical Marketing (MMM). The Company had previously announced the letter of intent to enter into an agreement with MMM back on February 27, 2015. As a result of the agreement, MMM will become the exclusive sales agent for BioCorRx within the Wellness Center category across the United States with the exception of licensee owned territories. The Company also recently announced a supply and distribution agreement with the first wellness center in Corona, CA for a pilot program. Four other wellness centers are planned to be a part of the pilot program. Upon the successful completion of the pilot program, MMM will introduce the Start Fresh Program into Physicians Business Solutions (PBS). PBS provides medical services and alternative revenue options to a network of 1000 medical centers nationwide. "Things are progressing nicely with this new endeavor. Now that we have the definitive agreement in place and a supply agreement with the first wellness center, we can focus on getting the pilot going," stated COO & interim CEO, Brady Granier.
Wealthmakers.com Initiates Coverage on BioCorRx (BICX)
GlobeNewswire - Mon Mar 23, 7:30AM CDT
BioCorRx, Inc. (BICX), developer of the Start Fresh Program(R) used for the treatment of alcohol and opioid dependence, announced today that WEALTHMAKERS.COM www.wealthmakers.com, a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals, and public company employees to make precise, predictive, and profitable trading decisions, has initiated coverage on BioCorRx (OTC: BICX). The report from Wealthmakers.com highlights a possible short term bullish pattern that has emerged and a SqueezeTrigger Price of $.225. Details about both and more can be found in the report immediately below.